Hello, Guest
Login
Sign Up
 
 

Stock Losers List: Peregrine Pharmaceuticals, MEMC Electronic Materials, Abercrombie & Fitch Co, Companhia Siderurgica Nacional

 
 
Repost This

Dallas, TX -- (SBWIRE) -- 03/22/2013 -- Marketbuzzreport.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-

Peregrine Pharmaceuticals (NASDAQ:PPHM) shares dropped 3.55% to $1.36. The company, on Mar. 12, announced financial results for the third quarter ended January 31, 2013 of fiscal year (FY) 2013 and provided an update on its advancing clinical pipeline and other corporate developments.

Total revenues for the third quarter of FY 2013 were $7,039,000 compared to $3,281,000, for the same quarter of the prior fiscal year. The company’s consolidated net loss decreased 56% to $4,914,000, or $0.04 per basic and diluted share, for the third quarter of FY 2013, compared to a net loss of $11,090,000, or $0.13 per basic and diluted share, for the same quarter of the prior year.

Is PPHM a Strong Buy After The Recent Gain? Let’s Find out Her e

MEMC Electronic Materials, Inc.(NYSE:WFR) shares decreased 3.45% to $4.48. WFR’s stock had its target price cut by UBS AG from $5.50 to $5.25 in a research note issued to investors on Mar. 18. The firm currently has a buy rating on the stock.

Additionally, the company, on Mar. 13, said it is filing a Form 8-K with the Securities and Exchange Commission to provide the slides that will be presented later today at the company's Capital Markets Day in Belmont, California, as well as a 2013 financial outlook and details on a forthcoming company name change proposal to shareholders.

Is WFR a Strong Buying Opportunity After The Recent Slump? Find out Here

Abercrombie & Fitch Co.(NYSE:ANF) shares dropped 3.41% to $45.94. Piper Jaffray reiterated their overweight rating on shares of ANF in a research report sent to investors on Mar. 19.

Additionally, the company announced its earnings results on Feb. 22. The company reported $2.21 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.96 by $0.25. The company had revenue of $1.47 billion for the quarter, compared to the consensus estimate of $1.49 billion.

Should Investors Consider ANF After The Recent price Action? Get Free Trend Analysis Here

Companhia Siderurgica Nacional (ADR)(NYSE:SID) shares fell 3.38% to $4.57. The company, on Feb. 7, announced that it has filed a lawsuit against the Grupo Ternium comprised of Confab Industrial SA, Prosid Investments SCA, Siderar SAIC and Ternium Investments Sarl. The entities named in the CSN lawsuit had acquired a 43.3% participation in Usinas Siderurgicas de Minas Gerais SA - Usiminas (Usiminas) in January 2012. The CSN lawsuit alleges that, under applicable Brazilian laws and rules, the acquirers were required to launch a tag-along tender offer to all minority holders of Usiminas ordinary shares for a price per share equal to 80% of the price per share paid in such acquisition and seeks an order to compel the acquirers to launch an offer at that price plus interest.

Should Investors Consider SID After The Recent price Action? Get Free Trend Analysis Here

About Marketbuzzreport.com
Marketbuzzreport.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. Marketbuzzreport.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed "informational edge" which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at http://www.marketbuzzreport.com

Disclaimer
The assembled information disseminated by Marketbuzzreport.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Marketbuzzreport.com does expect that investors will buy and sell securities based on information assembled and presented in Marketbuzzreport.com. PLEASE always do your own due diligence, and consult your financial advisor.